E2F5 and neoplasm: To assess whether increased E2F5‐mediated Drp1 activation increases cisplatin‐mediated tumor suppression, we generated HPV(−) UM‐SCC‐22A‐derived xenograft tumors in SCID mice, and measured the effects of E2F5‐pept or scr‐pept on tumor growth in the absence/presence of cisplatin (3.5 mg/kg every 3 days for 2 weeks).